Immunotherapy in non–small cell lung cancer: facts and hopes
DB Doroshow, MF Sanmamed, K Hastings, K Politi… - Clinical Cancer …, 2019 - AACR
Abstract Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have
altered the management of non–small cell lung cancer (NSCLC) over the last 10 years. First …
altered the management of non–small cell lung cancer (NSCLC) over the last 10 years. First …
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno …
S Hendry, R Salgado, T Gevaert… - Advances in anatomic …, 2017 - journals.lww.com
Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …
implications of this response are increasingly recognized, and as immunotherapies are …
The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion
CD8+ T cells are essential components of the immune response against viral infections and
tumours, and are capable of eliminating infected and cancerous cells. However, when the …
tumours, and are capable of eliminating infected and cancerous cells. However, when the …
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 …
SB Goldberg, KA Schalper, SN Gettinger… - The Lancet …, 2020 - thelancet.com
Background We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of …
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of …
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Abstract Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated
with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis …
with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis …
[HTML][HTML] Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3
Summary Lymphocyte-activation gene 3 (LAG-3) is an immune inhibitory receptor, with
major histocompatibility complex class II (MHC-II) as a canonical ligand. However, it remains …
major histocompatibility complex class II (MHC-II) as a canonical ligand. However, it remains …
Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
Purpose: Programmed death ligand 1 (PD-L1) is expressed in tumor cells and immune cells,
and both have been associated with response to anti-PD-1 axis immunotherapy. Here, we …
and both have been associated with response to anti-PD-1 axis immunotherapy. Here, we …
Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
Evidence indicates that lung cancer development is a complex process that involves
interactions between tumor cells, stromal fibroblasts, and immune cells. Tumor-infiltrating …
interactions between tumor cells, stromal fibroblasts, and immune cells. Tumor-infiltrating …
Classifying cancers based on T-cell infiltration and PD-L1
Cancer immunotherapy may become a major treatment backbone in many cancers over the
next decade. There are numerous immune cell types found in cancers and many …
next decade. There are numerous immune cell types found in cancers and many …
Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer
J McLaughlin, G Han, KA Schalper… - JAMA …, 2016 - jamanetwork.com
Importance Early-phase trials with monoclonal antibodies targeting PD-1 (programmed cell
death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable …
death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable …